{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:21:11Z","timestamp":1783635671818,"version":"3.55.0"},"reference-count":191,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.anl.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:05:08Z","timestamp":1776398708000},"page":"393-406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular biologic and Epstein-Barr virologic advances in extranodal natural killer\/T cell lymphoma over the past four decades"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2870-1277","authenticated-orcid":false,"given":"Yasuaki","family":"Harabuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.anl.2026.04.003_bib1","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/(SICI)1097-0142(19960515)77:10<2137::AID-CNCR27>3.0.CO;2-V","article-title":"Nasal T-cell lymphoma causally associated with Epstein-Barr virus: clinicopathologic, phenotypic, and genotypic studies","volume":"77","author":"Harabuchi","year":"1996","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.anl.2026.04.003_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10147-009-0882-7","article-title":"Nasal natural killer (NK)\/T-cell lymphoma: clinical, histological, virological, and genetic features","volume":"14","author":"Harabuchi","year":"2009","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"10.1016\/j.anl.2026.04.003_bib3","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1002\/1097-0142(19821201)50:11<2336::AID-CNCR2820501120>3.0.CO;2-C","article-title":"Nasal T-cell lymphoma as a type of so-called \"lethal midline granuloma\"","volume":"50","author":"Ishii","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.anl.2026.04.003_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/000348948509400223","article-title":"Midfacial T cell lymphoma: characterization by monoclonal antibodies","volume":"94","author":"Yamanaka","year":"1985","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib5","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/1097-0142(19850815)56:4<768::AID-CNCR2820560412>3.0.CO;2-W","article-title":"Non-Hodgkin's lymphoma of Waldeyer's ring and nasal cavity. Clinical and immunologic aspects","volume":"56","author":"Yamanaka","year":"1985","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.anl.2026.04.003_bib6","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0046-8177(87)80410-0","article-title":"Expression of natural killer cell markers in non-Hodgkin's lymphomas","volume":"18","author":"Ng","year":"1987","journal-title":"Hum Pathol"},{"issue":"7","key":"10.1016\/j.anl.2026.04.003_bib7","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"8682","key":"10.1016\/j.anl.2026.04.003_bib8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0140-6736(90)90002-M","article-title":"Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma","volume":"335","author":"Harabuchi","year":"1990","journal-title":"Lancet"},{"issue":"Pt 1","key":"10.1016\/j.anl.2026.04.003_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1099\/0022-1317-75-1-77","article-title":"Clonality, expression and methylation patterns of the Epstein-Barr virus genomes in lethal midline granulomas classified as peripheral angiocentric T cell lymphomas","volume":"75","author":"Minarovits","year":"1994","journal-title":"J Gen Virol"},{"issue":"3","key":"10.1016\/j.anl.2026.04.003_bib10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.V97.3.708","article-title":"Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T\/NK-cell lymphomas associated with the Epstein-Barr virus","volume":"97","author":"Nagata","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.anl.2026.04.003_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bjh.12136","article-title":"Expression of CD70 in nasal natural killer\/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27","volume":"160","author":"Yoshino","year":"2013","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.anl.2026.04.003_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.exphem.2013.03.009","article-title":"Soluble ICAM-1 secretion and its functional role as an autocrine growth factor in nasal NK\/T cell lymphoma cells","volume":"41","author":"Takahara","year":"2013","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib13","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41374-018-0182-9","article-title":"Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer\/T-cell lymphoma","volume":"99","author":"Nagato","year":"2019","journal-title":"Lab Invest"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib14","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.976077","article-title":"c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK\/T cell lymphoma","volume":"4","author":"Kumai","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.anl.2026.04.003_bib15","first-page":"174","article-title":"Metalloelastase expression in nasal NK\/T cell lymphoma","volume":"27","author":"Kishibe","year":"2007","journal-title":"J Immunol Allergy ORL"},{"issue":"7","key":"10.1016\/j.anl.2026.04.003_bib16","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00262-017-1987-x","article-title":"Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy","volume":"66","author":"Nagato","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"10.1016\/j.anl.2026.04.003_bib17","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1002\/ijc.22139","article-title":"Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3","volume":"119","author":"Takahara","year":"2006","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ijc.25969","article-title":"Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer\/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15","volume":"130","author":"Ishii","year":"2012","journal-title":"Int J Cancer"},{"issue":"23","key":"10.1016\/j.anl.2026.04.003_bib19","doi-asserted-by":"crossref","first-page":"8250","DOI":"10.1158\/1078-0432.CCR-05-1426","article-title":"Expression of interleukin-9 in nasal natural killer\/T-cell lymphoma cell lines and patients","volume":"11","author":"Nagato","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.anl.2026.04.003_bib20","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1158\/1078-0432.CCR-09-1052","article-title":"Production of interferon-{gamma}-inducible protein-10 and its role as an autocrine invasion factor in nasal natural killer\/T-cell lymphoma cells","volume":"15","author":"Moriai","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.anl.2026.04.003_bib21","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00262-015-1675-7","article-title":"CCL17 and CCL22\/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer\/T-cell lymphoma","volume":"64","author":"Kumai","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ajh.23570","article-title":"Downregulation of miR-15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK\/T-cell lymphoma","volume":"89","author":"Komabayashi","year":"2014","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.anl.2026.04.003_bib23","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41375-018-0324-5","article-title":"Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma","volume":"33","author":"Peng","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.anl.2026.04.003_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061414","article-title":"EBV and the Pathogenesis of NK\/T Cell Lymphoma","volume":"13","author":"Montes-Mojarro","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib25","article-title":"The Pathologic and Genetic Characteristics of Extranodal NK\/T-Cell Lymphoma","volume":"12","author":"Kim","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1016\/j.anl.2026.04.003_bib26","article-title":"Treatment of extranodal NK\/T-cell lymphoma: From past to future","volume":"14","author":"Yan","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.anl.2026.04.003_bib27","first-page":"64","article-title":"Photographs of a case of rapid destruction of the nose and face","volume":"12","author":"McBride","year":"1897","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.anl.2026.04.003_bib28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/bmj.2.3159.65","article-title":"Malignant granuloma of nose","volume":"2","author":"Woods","year":"1921","journal-title":"Brit Med J"},{"key":"10.1016\/j.anl.2026.04.003_bib29","first-page":"43","article-title":"Uber ein eigenartiges Granulom aer Nasen-, Rachen- und Mundhohle","volume":"24","author":"Kraus","year":"1929","journal-title":"Verh Dtsch Ges Pathol"},{"key":"10.1016\/j.anl.2026.04.003_bib30","first-page":"36","article-title":"\u00dcber eine eigentrige rhinogene Granulomatose mit besonderer Beteiligung des Artiensystems und der Nieren","volume":"102","author":"Wegener","year":"1939","journal-title":"Beitr Pathol Anat"},{"key":"10.1016\/j.anl.2026.04.003_bib31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/000348944905800405","article-title":"Lethal granulomatous ulceration, involving midline facial tissues","volume":"58","author":"Williams","year":"1949","journal-title":"Ann Otol Rhino Laryngol"},{"key":"10.1016\/j.anl.2026.04.003_bib32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1017\/S0022215100055250","article-title":"Non-healing glanuloma of the nose","volume":"73","author":"Walton","year":"1959","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.anl.2026.04.003_bib33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0002-9610(66)90328-X","article-title":"Primary lymphoma of the nose including a relationship to lethal midline granuloma","volume":"112","author":"Eichel","year":"1966","journal-title":"Am J Surg"},{"key":"10.1016\/j.anl.2026.04.003_bib34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/jcp.30.4.317","article-title":"Pathology of nonhealing (midline) granuloma","volume":"30","author":"Michaels","year":"1977","journal-title":"J Clin Path"},{"issue":"10","key":"10.1016\/j.anl.2026.04.003_bib35","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood.V81.10.2688.2688","article-title":"Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus","volume":"81","author":"Kanavaros","year":"1993","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib36","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00000478-199304000-00010","article-title":"Nasal lymphomas in Peru. High incidence of T-cell immunophenotype and Epstein-Barr virus infection [see comments]","volume":"17","author":"Arber","year":"1993","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib37","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1017\/S0022215100123485","article-title":"Nasal T-cell lymphoma associated with Epstein-Barr virus infection","volume":"107","author":"Dhaliwal","year":"1993","journal-title":"J Laryngol Otol"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib38","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.anl.2026.04.003_bib39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2559.1995.tb00333.x","article-title":"Nasal and nasal-type T\/NK cell lymphoma: a unique form of lymphoma associated with the Epstein-Barr virus","volume":"27","author":"Jaffe","year":"1995","journal-title":"Histopathology"},{"issue":"12","key":"10.1016\/j.anl.2026.04.003_bib40","first-page":"1419","article-title":"The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues","volume":"10","author":"Harris","year":"1999","journal-title":"Rep Clin Advis Comm Meet Airlie House Va Novemb 1997 Ann Oncol"},{"key":"10.1016\/j.anl.2026.04.003_bib41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1100\/tsw.2011.41","article-title":"Epidemiology and pathogenesis of nasal NK\/T-cell lymphoma: a mini-review","volume":"11","author":"Aozasa","year":"2011","journal-title":"ScientificWorldJournal"},{"issue":"25","key":"10.1016\/j.anl.2026.04.003_bib42","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International TCLP. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.anl.2026.04.003_bib43","first-page":"3055","article-title":"Pathological and clinical characteristics of 1,248 non-Hodgkin's lymphomas from a regional cancer hospital in Shandong, China","volume":"12","author":"Liu","year":"2011","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.anl.2026.04.003_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1750-1172-8-95","article-title":"Aggressive mature natural killer cell neoplasms: from epidemiology to diagnosis","volume":"8","author":"Lima","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/1097-0215(20000715)87:2<195::AID-IJC6>3.0.CO;2-0","article-title":"Low frequency of HLA-A*0201 allele in patients with Epstein-Barr virus-positive nasal lymphomas with polymorphic reticulosis morphology","volume":"87","author":"Kanno","year":"2000","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.anl.2026.04.003_bib46","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(16)30148-6","article-title":"Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study","volume":"17","author":"Li","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.anl.2026.04.003_bib47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41408-018-0149-5","article-title":"Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK\/T cell lymphoma","volume":"8","author":"Chan","year":"2018","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib48","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ijc.22313","article-title":"Life-style and environmental factors in the development of nasal NK\/T-cell lymphoma: a case-control study in East Asia","volume":"120","author":"Xu","year":"2007","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/1096-8652(200102)66:2<145::AID-AJH1033>3.0.CO;2-V","article-title":"Familial nasal NK\/T-cell lymphoma and pesticide use","volume":"66","author":"Kojya","year":"2001","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib50","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/annonc\/mdp418","article-title":"Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type","volume":"21","author":"Suzuki","year":"2010","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.anl.2026.04.003_bib51","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.clon.2008.05.011","article-title":"A clinical study of 115 patients with extranodal natural killer\/T-cell lymphoma, nasal type","volume":"20","author":"Wu","year":"2008","journal-title":"Clin Oncol (R Coll Radio)"},{"issue":"12","key":"10.1016\/j.anl.2026.04.003_bib52","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1182\/blood-2005-05-2056","article-title":"Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)\/II(E) extranodal NK\/T-cell lymphoma, nasal type","volume":"106","author":"Kim","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.anl.2026.04.003_bib53","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/PAS.0b013e31821ec4b5","article-title":"Clinicopathologic and molecular features of 122 Brazilian cases of nodal and extranodal NK\/T-cell lymphoma, nasal type, with EBV subtyping analysis","volume":"35","author":"Gualco","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib54","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.humpath.2014.11.008","article-title":"Extranodal natural killer\/T-cell lymphoma, nasal type in Taiwan: a relatively higher frequency of T-cell lineage and poor survival for extranasal tumors","volume":"46","author":"Jhuang","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.anl.2026.04.003_bib55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fped.2019.00141","article-title":"Extranodal natural killer\/T-Cell lymphoma, nasal type: basic science and clinical progress","volume":"7","author":"Harabuchi","year":"2019","journal-title":"Front Pedia"},{"issue":"7","key":"10.1016\/j.anl.2026.04.003_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9071381","article-title":"Extranodal NK\/T-cell lymphoma, nasal type: genetic, biologic, and clinical aspects with a central focus on epstein-barr virus relation","volume":"9","author":"Takahara","year":"2021","journal-title":"Microorganisms"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib57","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood.V87.4.1466.bloodjournal8741466","article-title":"CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas","volume":"87","author":"Emile","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00000478-199601000-00012","article-title":"Report of the workshop on nasal and related extranodal angiocentric t\/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology","volume":"20","author":"Jaffe","year":"1996","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib59","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/1097-0142(19920815)70:4<835::AID-CNCR2820700419>3.0.CO;2-F","article-title":"Lethal midline granuloma (peripheral T-cell lymphoma) after lymphomatoid papulosis","volume":"70","author":"Harabuchi","year":"1992","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib60","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/PAS.0b013e31824433d8","article-title":"Extranodal NK\/T-cell lymphoma, nasal type, includes cases of natural killer cell and alphabeta, gammadelta, and alphabeta\/gammadelta T-cell origin: a comprehensive clinicopathologic and phenotypic study","volume":"36","author":"Pongpruttipan","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11262-006-0008-5","article-title":"Sequence variations of Epstein-Barr virus LMP1 gene in nasal NK\/T-cell lymphoma","volume":"34","author":"Nagamine","year":"2007","journal-title":"Virus Genes"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib62","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000106462","article-title":"Selected amino acid change encoding Epstein-Barr virus-specific T cell epitope of the LMP2A gene in Japanese nasal NK\/T cell lymphoma patients","volume":"50","author":"Nagamine","year":"2007","journal-title":"Intervirology"},{"issue":"5-6","key":"10.1016\/j.anl.2026.04.003_bib63","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/10428199909169621","article-title":"Nasal lymphomas in Japan: a high prevalence of Epstein-Barr virus type A and deletion within the latent membrane protein gene","volume":"35","author":"Suzumiya","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib64","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/(SICI)1096-9071(199612)50:4<314::AID-JMV6>3.0.CO;2-B","article-title":"Genomic analysis of Epstein-Barr virus in nasal and peripheral T-cell lymphoma: a comparison with nasopharyngeal carcinoma in an endemic area","volume":"50","author":"Wu","year":"1996","journal-title":"J Med Virol"},{"issue":"7","key":"10.1016\/j.anl.2026.04.003_bib65","first-page":"1549","article-title":"High prevalence of a 30-base pair deletion and single-base mutations within the carboxy terminal end of the LMP-1 oncogene of Epstein-Barr virus in the Japanese population","volume":"13","author":"Itakura","year":"1996","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.anl.2026.04.003_bib66","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood.V88.9.3491.bloodjournal8893491","article-title":"Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations","volume":"88","author":"Khanim","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib67","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/jmv.20129","article-title":"Epstein-barr virus (EBV) in healthy carriers: distribution of genotypes and 30 bp deletion in latent membrane protein-1 (LMP-1) oncogene","volume":"73","author":"Correa","year":"2004","journal-title":"J Med Virol"},{"issue":"13","key":"10.1016\/j.anl.2026.04.003_bib68","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1128\/JVI.77.13.7401-7410.2003","article-title":"Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions","volume":"77","author":"Duraiswamy","year":"2003","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.anl.2026.04.003_bib69","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.4049\/jimmunol.158.7.3325","article-title":"Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy","volume":"158","author":"Lee","year":"1997","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib70","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/A:1008171006400","article-title":"Sequence variations of Epstein-Barr virus LMP2A gene in gastric carcinoma in Japan","volume":"19","author":"Tanaka","year":"1999","journal-title":"Virus Genes"},{"key":"10.1016\/j.anl.2026.04.003_bib71","doi-asserted-by":"crossref","first-page":"865","DOI":"10.4049\/jimmunol.146.3.865","article-title":"Expression of CR2 (the CD3dg\/EBV receptor, CD21) on normal human peripheral blood T lymphocytes","volume":"146","author":"Fischer","year":"1991","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.anl.2026.04.003_bib72","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/intimm\/11.11.1841","article-title":"Expression of CD21 is developmentally regulated during thymic maturation of human T lymphocytes","volume":"11","author":"Fischer","year":"1999","journal-title":"Int Immunol"},{"issue":"7","key":"10.1016\/j.anl.2026.04.003_bib73","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/infdis\/jiaa232","article-title":"Patients with natural killer (NK) cell chronic active epstein-barr virus have immature NK cells and hyperactivation of PI3K\/Akt\/mTOR and STAT1 pathways","volume":"222","author":"Howe","year":"2020","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.05.018","article-title":"Pathogenic role of Epstein-Barr virus latent membrane protein-1 in the development of nasopharyngeal carcinoma","volume":"337","author":"Yoshizaki","year":"2013","journal-title":"Cancer Lett"},{"issue":"20","key":"10.1016\/j.anl.2026.04.003_bib75","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1093\/emboj\/16.20.6131","article-title":"Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule","volume":"16","author":"Gires","year":"1997","journal-title":"Embo J"},{"issue":"11","key":"10.1016\/j.anl.2026.04.003_bib76","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1093\/emboj\/18.11.3064","article-title":"Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins","volume":"18","author":"Gires","year":"1999","journal-title":"Embo J"},{"issue":"23","key":"10.1016\/j.anl.2026.04.003_bib77","doi-asserted-by":"crossref","first-page":"16085","DOI":"10.1074\/jbc.274.23.16085","article-title":"Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production","volume":"274","author":"Eliopoulos","year":"1999","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.anl.2026.04.003_bib78","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00006-22","article-title":"LMP1 Induces p53 Protein Expression via the H19\/miR-675-5p Axis","volume":"10","author":"Li","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"10","key":"10.1016\/j.anl.2026.04.003_bib79","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","article-title":"Epstein-Barr virus: 40 years on","volume":"4","author":"Young","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib80","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40880-018-0334-8","article-title":"IL-2R\u03b1 up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer\/T-cell lymphoma","volume":"38","author":"Wang","year":"2018","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib81","doi-asserted-by":"crossref","first-page":"E686","DOI":"10.1073\/pnas.1713607115","article-title":"Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4(+) and CD8(+) T cell responses","volume":"115","author":"Choi","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib82","first-page":"104","article-title":"Transient expression of the Epstein-Barr virus LMP1 gene in B-cell chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: cell-type-independent-induction of CD23, CD21, and ICAM-1","volume":"7","author":"Peng","year":"1993","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib83","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0002-9440(10)61669-0","article-title":"Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma","volume":"159","author":"Horikawa","year":"2001","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.anl.2026.04.003_bib84","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1073\/pnas.95.7.3621","article-title":"The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1","volume":"95","author":"Yoshizaki","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib85","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 is upregulated by EBV-driven LMP1 through NF-\u03baB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib86","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/viro.2000.0768","article-title":"The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38\/SAPK2 pathway","volume":"280","author":"Vockerodt","year":"2001","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib87","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ijc.20759","article-title":"The Epstein-Barr virus oncoprotein latent membrane protein 1 induces expression of the chemokine IP-10: importance of mRNA half-life regulation","volume":"114","author":"Vockerodt","year":"2005","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib88","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1349-7006.2007.00687.x","article-title":"Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder","volume":"99","author":"Takegawa","year":"2008","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.anl.2026.04.003_bib89","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1046\/j.1365-2141.1997.752711.x","article-title":"Clonal chromosomal abnormalities as direct evidence for clonality in nasal T\/natural killer cell lymphomas","volume":"97","author":"Tien","year":"1997","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.anl.2026.04.003_bib90","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1080\/1042819031000123410","article-title":"Deletion mapping of the long arm of chromosome 6 in peripheral T and NK cell lymphomas","volume":"44","author":"Yoon","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.anl.2026.04.003_bib91","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood-2011-04-346890","article-title":"Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses","volume":"118","author":"Karube","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.anl.2026.04.003_bib92","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/435423","article-title":"The Genetic Deletion of 6q21 and PRDM1 and Clinical Implications in Extranodal NK\/T Cell Lymphoma, Nasal Type","volume":"2015","author":"Liang","year":"2015","journal-title":"Biomed Res Int"},{"issue":"10","key":"10.1016\/j.anl.2026.04.003_bib93","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2014-07-588970","article-title":"Receptor-type tyrosine-protein phosphatase kappa directly targets STAT3 activation for tumor suppression in nasal NK\/T-cell lymphoma","volume":"125","author":"Chen","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.anl.2026.04.003_bib94","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2009.3","article-title":"Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies","volume":"23","author":"Iqbal","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.anl.2026.04.003_bib95","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2008-12-194852","article-title":"TNFAIP3\/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas","volume":"114","author":"Honma","year":"2009","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.anl.2026.04.003_bib96","doi-asserted-by":"crossref","first-page":"17764","DOI":"10.18632\/oncotarget.3776","article-title":"Genetic alterations of JAK\/STAT cascade and histone modification in extranodal NK\/T-cell lymphoma nasal type","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.anl.2026.04.003_bib97","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/2159-8290.CD-12-0028","article-title":"Janus kinase 3-activating mutations identified in natural killer\/T-cell lymphoma","volume":"2","author":"Koo","year":"2012","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib98","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/leu.2013.157","article-title":"JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma","volume":"28","author":"Bouchekioua","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.anl.2026.04.003_bib99","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/leu.2009.91","article-title":"STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK\/T-cell lymphoma","volume":"23","author":"Coppo","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib100","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/leu.2010.255","article-title":"Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro","volume":"25","author":"Iqbal","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.anl.2026.04.003_bib101","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2009-05-221275","article-title":"Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK\/T-cell lymphoma, nasal type","volume":"115","author":"Huang","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.anl.2026.04.003_bib102","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2016-01-690701","article-title":"EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer\/T-cell lymphoma","volume":"128","author":"Yan","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.anl.2026.04.003_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1175545","article-title":"Extranodal NK-\/T-cell lymphoma, nasal type: what advances have been made in the last decade?","volume":"13","author":"Costa","year":"2023","journal-title":"Front Oncol"},{"issue":"20","key":"10.1016\/j.anl.2026.04.003_bib104","doi-asserted-by":"crossref","first-page":"29804","DOI":"10.18632\/oncotarget.7772","article-title":"Notch signaling: its roles and therapeutic potential in hematological malignancies","volume":"7","author":"Gu","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.anl.2026.04.003_bib105","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1093\/emboj\/18.10.2803","article-title":"Rel\/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors","volume":"18","author":"Bash","year":"1999","journal-title":"Embo J"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib106","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/path.2823","article-title":"Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK\/T cell lymphoma revealed by gene expression profiling","volume":"223","author":"Ng","year":"2011","journal-title":"J Pathol"},{"issue":"12","key":"10.1016\/j.anl.2026.04.003_bib107","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1007\/s00277-024-06035-w","article-title":"Mutational characteristics of extranodal NK\/T-cell lymphoma analyzed in relation to clinical prognostic indices","volume":"103","author":"Lee","year":"2024","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib108","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2011.08898.x","article-title":"The potential role of Aurora kinase inhibitors in haematological malignancies","volume":"155","author":"Farag","year":"2011","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.anl.2026.04.003_bib109","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev"},{"issue":"9","key":"10.1016\/j.anl.2026.04.003_bib110","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1101\/gad.381706","article-title":"Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions","volume":"20","author":"Bracken","year":"2006","journal-title":"Genes Dev"},{"issue":"7","key":"10.1016\/j.anl.2026.04.003_bib111","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7150\/ijbs.9067","article-title":"Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications","volume":"10","author":"Li","year":"2014","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib112","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1084\/jem.20081242","article-title":"Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs","volume":"206","author":"Cruz-Guilloty","year":"2009","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.anl.2026.04.003_bib113","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1038\/leu.2017.40","article-title":"RUNX3 is oncogenic in natural killer\/T-cell lymphoma and is transcriptionally regulated by MYC","volume":"31","author":"Selvarajan","year":"2017","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.anl.2026.04.003_bib114","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood-2008-12-194290","article-title":"Aurora kinase A is a target of Wnt\/beta-catenin involved in multiple myeloma disease progression","volume":"114","author":"Dutta-Simmons","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/0008-5472.CAN-03-2907","article-title":"Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells","volume":"64","author":"Yang","year":"2004","journal-title":"Cancer Res"},{"issue":"50","key":"10.1016\/j.anl.2026.04.003_bib116","doi-asserted-by":"crossref","first-page":"52175","DOI":"10.1074\/jbc.M406802200","article-title":"Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215","volume":"279","author":"Liu","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.anl.2026.04.003_bib117","unstructured":"Huang Y., Zhang L., Lin L., Chen B., Wang L., Chen L., et al. Activation of PDGFR\u03b1 by EBV-LMP1 promotes cell proliferation and invasion in extranodal NK\/T-cell lymphoma\" was published in in 2018 (Vol. 32, Issue 11, pp.), authored by Leukemia. 2018;32(11):2315\u20132325."},{"issue":"22","key":"10.1016\/j.anl.2026.04.003_bib118","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","article-title":"EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity","volume":"121","author":"Yan","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib119","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.humpath.2003.08.025","article-title":"P53, N- and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK\/T-cell lymphoma from Hokkaido, Japan","volume":"35","author":"Takahara","year":"2004","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib120","first-page":"265","article-title":"p53, K-ras, c-kit and beta-catenin gene mutations in sinonasal NK\/T-cell lymphoma in Korea and Japan","volume":"13","author":"Hongyo","year":"2005","journal-title":"Oncol Rep"},{"issue":"18","key":"10.1016\/j.anl.2026.04.003_bib121","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1182\/blood-2011-07-364224","article-title":"Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer\/T-cell lymphoma","volume":"118","author":"Ng","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib122","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.ajpath.2013.01.025","article-title":"Epstein-Barr virus-encoded miR-BART20-5p inhibits T-bet translation with secondary suppression of p53 in invasive nasal NK\/T-cell lymphoma","volume":"182","author":"Lin","year":"2013","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.anl.2026.04.003_bib123","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1073\/pnas.97.7.3260","article-title":"Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion","volume":"97","author":"Coller","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib124","doi-asserted-by":"crossref","first-page":"793","DOI":"10.7150\/jca.17766","article-title":"Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK\/T-cell Lymphoma, Nasal Type","volume":"8","author":"Wang","year":"2017","journal-title":"J Cancer"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1074\/jbc.M609138200","article-title":"BCL2 is a downstream effector of MIZ-1 essential for blocking c-MYC-induced apoptosis","volume":"282","author":"Patel","year":"2007","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.anl.2026.04.003_bib126","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0167-5699(94)90077-9","article-title":"CD27: marker and mediator of T-cell activation?","volume":"15","author":"Hintzen","year":"1994","journal-title":"Immunol Today"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib127","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.4049\/jimmunol.135.2.1020","article-title":"Functional characterization of LFA-1 antigens in the interaction of human NK clones and target cells","volume":"135","author":"Schmidt","year":"1985","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.anl.2026.04.003_bib128","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"26","key":"10.1016\/j.anl.2026.04.003_bib129","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1200\/JCO.2011.40.3774","article-title":"Targeting the hepatocyte growth factor-cMET axis in cancer therapy","volume":"30","author":"Blumenschein","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib130","first-page":"1","article-title":"Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture","volume":"46","author":"Liotta","year":"1986","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib131","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1016\/j.anl.2026.04.003_bib132","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/000348949610500809","article-title":"Circulating intercellular adhesion molecule-1 and its cellular expression in head and neck non-Hodgkin's lymphomas, including lethal midline granuloma","volume":"105","author":"Harabuchi","year":"1996","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib133","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13045-019-0716-7","article-title":"Molecular pathogenic pathways in extranodal NK\/T cell lymphoma","volume":"12","author":"de Mel","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"10168","key":"10.1016\/j.anl.2026.04.003_bib134","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.anl.2026.04.003_bib135","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/1471-2407-7-229","article-title":"The enhanced expression of the matrix metalloproteinase 9 in nasal NK\/T-cell lymphoma","volume":"7","author":"Sakata","year":"2007","journal-title":"BMC Cancer"},{"issue":"3-4","key":"10.1016\/j.anl.2026.04.003_bib136","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/08830189809043001","article-title":"Interleukin 9 and its receptor: an overview of structure and function","volume":"16","author":"Demoulin","year":"1998","journal-title":"Int Rev Immunol"},{"issue":"6","key":"10.1016\/j.anl.2026.04.003_bib137","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/jir.2023.0035","article-title":"The Dichotomy of Interleukin-9 Function in the Tumor Microenvironment","volume":"43","author":"Cannon","year":"2023","journal-title":"J Interferon Cytokine Res"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib138","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/1097-0215(20010601)92:5<692::AID-IJC1237>3.0.CO;2-Z","article-title":"Expression of HLA class I, beta(2)-microglobulin, TAP1 and IL-10 in Epstein-Barr virus-associated nasal NK\/T-cell lymphoma: Implications for tumor immune escape mechanism","volume":"92","author":"Shen","year":"2001","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.anl.2026.04.003_bib139","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1182\/blood-2001-12-0293","article-title":"vivo evidence for a dependence on interleukin 15 for survival of natural killer cells","volume":"100","author":"Cooper","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.anl.2026.04.003_bib140","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.4049\/jimmunol.155.8.3877","article-title":"Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis","volume":"155","author":"Taub","year":"1995","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib141","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2025.2538962","article-title":"Dual role of CXCL10 in cancer progression: implications for immunotherapy and targeted treatment\u200e","volume":"26","author":"Madkhali","year":"2025","journal-title":"Cancer Biol Ther"},{"issue":"21","key":"10.1016\/j.anl.2026.04.003_bib142","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218412","article-title":"CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"14","key":"10.1016\/j.anl.2026.04.003_bib143","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1073\/pnas.141224998","article-title":"Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway","volume":"98","author":"Baldassarre","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.anl.2026.04.003_bib144","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1158\/0008-5472.CAN-06-0261","article-title":"Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege","volume":"66","author":"Ishida","year":"2006","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1158\/0008-5472.CAN-08-0377","article-title":"A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle","volume":"69","author":"Cohen","year":"2009","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.anl.2026.04.003_bib146","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood.V93.10.3531.410k32_3531_3539","article-title":"Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15","volume":"93","author":"Musso","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib147","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hon.2273","article-title":"Novel treatment for early-stage nasal natural killer\/T-cell lymphoma: intra-maxillary arterial infusion chemotherapy with concomitant radiotherapy","volume":"35","author":"Takahara","year":"2017","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib148","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/jmv.20853","article-title":"Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for Nasal NK\/T-cell lymphoma","volume":"79","author":"Ishii","year":"2007","journal-title":"J Med Virol"},{"issue":"23","key":"10.1016\/j.anl.2026.04.003_bib149","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1182\/blood-2011-05-354142","article-title":"Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK\/T-cell lymphoma, nasal type","volume":"118","author":"Suzuki","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib150","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/hon.2360","article-title":"Circulating Epstein-Barr virus-encoded micro-RNAs as potential biomarkers for nasal natural killer\/T-cell lymphoma","volume":"35","author":"Komabayashi","year":"2017","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib151","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1155\/2010\/474692","article-title":"Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer\/T-cell lymphoma","volume":"29","author":"Guo","year":"2010","journal-title":"Dis Markers"},{"issue":"7","key":"10.1016\/j.anl.2026.04.003_bib152","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00262-023-03394-7","article-title":"Expression of soluble CD27 in extranodal natural killer\/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27\/CD70-targeted therapy","volume":"72","author":"Nagato","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib153","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11899-018-0430-5","article-title":"NK\/T cell lymphoma: updates in therapy","volume":"13","author":"Suzuki","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib154","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12185-019-02609-x","article-title":"JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-9. Extranodal NK\/T-cell lymphoma, nasal type (ENKL)","volume":"109","author":"Yamaguchi","year":"2019","journal-title":"Int J Hematol"},{"issue":"20","key":"10.1016\/j.anl.2026.04.003_bib155","doi-asserted-by":"crossref","first-page":"29092","DOI":"10.18632\/oncotarget.8647","article-title":"Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed\/refractory extranodal NK\/T-cell lymphoma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.anl.2026.04.003_bib156","doi-asserted-by":"crossref","first-page":"795","DOI":"10.20892\/j.issn.2095-3941.2020.0160","article-title":"Outcomes of patients treated with SVILE vs. P-GemOx for extranodal natural killer\/T-cell lymphoma, nasal type: a prospective, randomized controlled study","volume":"17","author":"Wei","year":"2020","journal-title":"Cancer Biol Med"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib157","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41375-025-02527-4","article-title":"Improved prognosis of advanced-stage extranodal NK\/T-cell lymphoma: results of the NKEA-Next study","volume":"39","author":"Fujimoto","year":"2025","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib158","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051366","article-title":"Rational targets of therapy in extranodal NK\/T-Cell Lymphoma","volume":"15","author":"Major","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.anl.2026.04.003_bib159","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.anl.2026.04.003_bib160","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib161","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-020-01020-y","article-title":"Daratumumab monotherapy for patients with relapsed or refractory natural killer\/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study","volume":"14","author":"Huang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib162","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.annonc.2020.12.009","article-title":"Combination treatment of copanlisib and gemcitabine in relapsed\/refractory PTCL (COSMOS): an open-label phase I\/II trial","volume":"32","author":"Yhim","year":"2021","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.anl.2026.04.003_bib163","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1182\/blood.V128.22.5353.5353","article-title":"S.T. A Phase II Study of Bortezomib-GIFOX (Gemcitabine, Ifosfamide, Oxaliplatin) in patients with newly diagnosed natural-killer\/T-cell lymphoma","volume":"128","author":"Tang","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.anl.2026.04.003_bib164","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.anl.2026.04.003_bib165","article-title":"A multi-center, real-world study of chidamide for patients with relapsed or refractory peripheral T-cell lymphomas in China","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib166","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00428-016-2011-0","article-title":"Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK\/T cell lymphoma is associated with better prognosis","volume":"469","author":"Kim","year":"2016","journal-title":"Virchows Arch"},{"issue":"17","key":"10.1016\/j.anl.2026.04.003_bib167","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib168","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4143\/crt.2023.1042","article-title":"Pembrolizumab for patients with relapsed or refractory extranodal NK\/T-cell lymphoma in Korea","volume":"56","author":"Lee","year":"2024","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib169","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","article-title":"Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)","volume":"6","author":"Tao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.anl.2026.04.003_bib170","article-title":"Phase 2 study of anti-PD-L1 antibody atezolizumab in patients with relapsed\/refractory extranodal natural killer\/T-cell lymphoma: NCCH1903\/ATTACK study","author":"Makita","year":"2024","journal-title":"Eur Hematol Assoc"},{"issue":"16","key":"10.1016\/j.anl.2026.04.003_bib171","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.02367","article-title":"Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer\/T-cell lymphoma (GEMSTONE-201): results from a single-arm, multicenter, phase II study","volume":"41","author":"Huang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.anl.2026.04.003_bib172","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: an open-label phase 2 study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.anl.2026.04.003_bib173","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1182\/bloodadvances.2022009575","article-title":"Treating relapsed\/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study","volume":"7","author":"Bachy","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib174","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood.2024027109","article-title":"Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed\/refractory NK\/T-cell lymphoma","volume":"146","author":"Kim","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41392-024-01825-0","article-title":"Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib\/II study","volume":"9","author":"Gao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib176","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1182\/blood-2024-207344","article-title":"Efficacy and safety of combined Anti-PD-1, bortezomib and pegaspargase regimen for newly diagnosed early stage extranodal NK\/T-cell lymphoma","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib177","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/hon.2325","article-title":"A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer\/T-cell lymphoma, nasal type: a multicenter trial in Northwest China","volume":"35","author":"Liang","year":"2017","journal-title":"Hematol Oncol"},{"issue":"7","key":"10.1016\/j.anl.2026.04.003_bib178","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/ajh.26922","article-title":"A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first-line therapy in patients with newly diagnosed, stage I-II extranodal natural-killer\/T-cell lymphoma","volume":"98","author":"Sun","year":"2023","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib179","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1016\/S2352-3026(24)00066-8","article-title":"First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer\/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial","volume":"11","author":"Tian","year":"2024","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.anl.2026.04.003_bib180","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib181","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.anl.2026.04.003_bib182","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/(SICI)1521-4141(199802)28:02<451::AID-IMMU451>3.0.CO;2-U","article-title":"Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes","volume":"28","author":"Khanna","year":"1998","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.anl.2026.04.003_bib183","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/eji.200535485","article-title":"Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies","volume":"36","author":"Demachi-Okamura","year":"2006","journal-title":"Eur J Immunol"},{"issue":"8","key":"10.1016\/j.anl.2026.04.003_bib184","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.anl.2026.04.003_bib185","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/mt.2015.91","article-title":"Long-term outcome of extranodal NK\/T cell lymphoma patients treated with postremission therapy using EBV LMP1 and LMP2a-specific CTLs","volume":"23","author":"Cho","year":"2015","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.anl.2026.04.003_bib186","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/bjc.2017.475","article-title":"A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy","volume":"118","author":"Cho","year":"2018","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.anl.2026.04.003_bib187","first-page":"922","article-title":"Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function","volume":"8","author":"Giuntoli","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2026.04.003_bib188","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/1479-5876-9-191","article-title":"Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer","volume":"9","author":"Hayashi","year":"2011","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.anl.2026.04.003_bib189","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1158\/0008-5472.CAN-07-3212","article-title":"Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells","volume":"68","author":"Kobayashi","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.anl.2026.04.003_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100770","article-title":"Efficacy of B7-H3-redirected BiTE and CAR-T immunotherapies against extranodal nasal natural killer\/T cell lymphoma","volume":"13","author":"Zheng","year":"2020","journal-title":"Transl Oncol"},{"issue":"1","key":"10.1016\/j.anl.2026.04.003_bib191","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12916-023-03040-0","article-title":"CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK\/T cell lymphoma","volume":"21","author":"Li","year":"2023","journal-title":"BMC Med"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814626000520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814626000520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:02:36Z","timestamp":1783634556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814626000520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":191,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0385814626000520"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2026.04.003","relation":{},"ISSN":["0385-8146"],"issn-type":[{"value":"0385-8146","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular biologic and Epstein-Barr virologic advances in extranodal natural killer\/T cell lymphoma over the past four decades","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}